Connect with us

Global Market

Ambulatory Surgical Centers Market Expected to Witness Healthy Growth Rates

Published

on

Press Release

Global Ambulatory Surgical Centers Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables).

Ambulatory Surgical Centers Market by Type (Hospital-Affiliated Ambulatory Surgical Centers [Single-Specialty Centers and Multi-Specialty Centers], and Freestanding Ambulatory Surgical Centers [Single-Specialty Centers and Multi-Specialty Centers]), and by Service (Diagnostics Service and Surgical Service) – Global Opportunity Analysis and Industry Forecast, 2020-2027

 

Download PDF Report Sample with statistical info @ https://www.alliedmarketresearch.com/request-toc-and-sample/4040

 

Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key players that operate in the market are AmSurgUnited Surgical Partners, Surgery Partners, Surgical Care Affiliates, Envision Healthcare Holdings, Mednax, Team Health Holdings, Tenet Healthcare, SurgCenter Development and Suprabha Surgicare.

 

KEY BENEFITS FOR STAKEHOLDERS

  • The Ambulatory Surgical Centers Market size has been analyzed across all regions.
  • Porter’s five force analysis helps to analyze the potential of buyers & suppliers and the competitive scenario of the industry for strategy building
  • The report outlines the current market trends and future scenario of the market size from 2019 to 2027 to understand the prevailing opportunities and potential investment pockets.
  • Major countries in the regions have been mapped according to their individual revenue contribution.
  • The key drivers, restraints, and market opportunities and their detailed impact analysis are elucidated in the study.
  • The market analysis covers in-depth information of major industry participants.

KEY MARKET SEGMENTS

By Type

  • Hospital-affiliated ASCs
    • Single-Specialty Centers
    • Multi-Specialty Centers
  • Freestanding ASCs
    • Single-Specialty Centers
    • Multi-Specialty Centers

By Service

  • Diagnostic Service
  • Surgical Service

Global Market

Global Type 1 Hyperlipoproteinemia Drugs Market is expected to grow at a CAGR of 8.8% from 2020 to 2027

Published

on

Press Release

Type 1 hyperlipoproteinemia is also called familial lipoprotein lipase deficiency is an inherited genetic disorder, it is a rare disease with a global prevalence rate of 1 to 2 per 1,000,000 people. Currently the drugs used for its clinical treatment are Alipogene Tiparvovec, lomitapide mesylate, pradigastat sodium, etc.

Hypertriglyceridemia is dominating the indication segment for the type 1 hyperlipoproteinemia drug market. It is manifested by the triglyceride blood serum level of above 500mg/dl. The excess levels of triglyceride and chylomicrons in the blood are due to a lack of familial lipoprotein lipase deficiency and familial apolipoprotein C-II deficiency in certain cases. In the later stage of life it results in cardiovascular complications in the patients. Acute pancreatitis is the first clinical manifestation occurring in patients suffering from type 1 hyperlipoproteinemia. Intense bouts of abdominal pain occur due to the inflammation of the pancreas and it possesses a great risk of diabetes in the later stage of life. Eruptive xanthomas are the fastest growing indication segment, primarily due to its occurrence in approximately 50% of the patients having familial lipoprotein lipase deficiency, small localized bumps, and plaques appear on the skin suffer on account of the deposition of lipids in the tendons, skin and subcutaneous tissues.

Browse the full report Type 1 Hyperlipoproteinemia Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/type-1-hyperlipoproteinemia-drugs-market

Hospital pharmacy is dominating the distribution channel segment for the type 1 hyperlipoproteinemia drug market. The availability of hospital pharmacist is vital in order to prepare accurate drug posology prescribed for the treatment of type 1 hyperlipoproteinemia, in order to prevent any drug-related side effects. The retail pharmacy will be the fastest-growing segment during the forecast period in the developing countries owing to its ability to provide prescribed and OTC medicines 24/7 especially in remote locations and relatively low cost.

North America is reigning the geographical segment for the type 1 hyperlipoproteinemia drugs market. The rising prevalence of acute pancreatitis is primarily driving its market growth. As per the latest statistics provided by the Center for Disease Control and Prevention (CDC), approximately one-fourth of theU.S. adult citizens are reported to be suffering from hypertriglyceridemia. Further diagnosis has revealed that it is linked with chylomicron abnormalities in the human blood. The supportive regulatory environment provided by the USFDA by awarding fast track designation status for the drug development to be used in the treatment of rare diseases accentuates the type 1 hyperlipoproteinemia drug market. Europe is the second-largest market owing to the strategic partnership between the academic research institutes and biopharmaceutical companies to develop a gene therapy to treat lipoprotein lipase disorders. Furthermore affordable reimbursement scenario for the drugs employed in the treatment of type 1 hyperlipoproteinemia further propels its market growth in the region. Asia Pacific is set to record magnificent market growth in the near future on account of the developing healthcare infrastructure and large funds allotted by the healthcare agencies to develop novel medicines for the treatment of familial liposome lipase deficiency.

Biopharmaceutical companies actively engaged in providing medicines for the treatment of type 1 hyperlipoproteinemia are Aegerion Pharmaceuticals, Inc., Novartis AG., Isis Pharmaceuticals, Inc., uniQure N.V., Catabasis Pharmaceuticals, Inc., Anji Pharma, Chiesi Farmaceutici., Arrowhead Pharmaceuticals., Ionis Pharmaceuticals, Inc., and BASF SE.

Market Key Takeaways:

  • A constant rise in the number of patients suffering with lipoprotein lipase deficiency
  • Proactive role adopted by the global healthcare regulatory agencies for the novel drug development for the treatment of type 1 hyperlipoproteinemia
  • Affordable reimbursement scenario for the costly medication used in the treatment of rare disease worldwide

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]

Continue Reading

Global Market

Global Plasminogen Market Is Expected To Grow At A CAGR Of 4.1% From 2020 To 2027

Published

on

Press Release

Plasminogen is an inactive form of plasmin released by the liver in the systemic circulation, it is a serine protease and its objective is the dissolution of fibrin blood clots. Acquired and hereditary plasminogen deficiency increases the risk of thromboembolic disease.

Thrombosis is dominating the application segment for the plasminogen market. Rising prevalence of pulmonary embolism in elderly patients and a significant increase in the inherited plasminogen deficiency of plasminogen together drive the market growth.  As per the recent research findings provided by the World Health Organization (WHO), the prevalence rate associated with deep vein thrombosis is 1 to 2 per 1000 people each year. Ischemic heart disease will be showcasing remarkable market growth during the forecast period owing to the constant rise in the adoption of an unhealthy lifestyle, diet, stress, and high consumption of tobacco and alcohol worldwide. As per the latest research citings provided by the World Health Organization (WHO), approximately 15 million people suffer from stroke throughout the globe each year.

Hospitals and clinics are presently leading the end-user segment for the plasminogen market. The key factor responsible for its positive market growth is the rising prevalence of ischemic heart diseases and venous thromboembolism worldwide. Patients need to be immediately hospitalized in the critical care unit to remove the clot present in the venous system to prevent fatality and mortality associated with the disease. Ambulatory surgical centers will be growing at a rampant market growth in the near future to its ability to provide emergency medical aid to patients suffering from myocardial infarction in remote locations.

Browse the full report Plasminogen Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/plasminogen-market

North America is currently spearheading the geography segment for the plasminogen market. The major factor associated with its market dominance is the rising prevalence of deep vein thrombosis in the region. According to the latest statistics provided by the Center for Disease Control and Prevention (CDC), approximately the prevalence rate associated with deep vein thrombosis is 1 to 2 per 1,000 per year in the United States. Affordable reimbursement scenario and supportive regulatory environment provided by the USFDA pertaining to the manufacture and sale of plasminogen provides a boost to the market growth in the region. Europe stood 2nd in the regional segment for the plasminogen market on account of the rising prevalence of ischemic heart disease in the European Union. As per the latest research citings presented by the European Heart Network (EHN), each year cardiovascular disease causes approximately 3.9 million deaths in the region. Asia Pacific is anticipated to be the fastest-growing regional segment during the forecast period owing to the developing healthcare infrastructure and constant rise in the medical tourism industry in the Asia Pacific region.

Biopharmaceutical manufacturers actively engaged in the production of plasminogen are Diapharma, Kedrion S.p.A., Liminal BioSciences, Genentech, Inc. (Roche), Boehringer Ingelheim, Kyowa Hakko Kirin, Omeros Corporation, Bayer AG, Cadila Healthcare Ltd, and Merck & Co.

Market Key Takeaway:

  • Rising prevalence of ischemic heart diseases worldwide
  • Significant increase in the number of people suffering from venous thromboembolism throughout the globe
  • The supportive regulatory environment provided by the global healthcare agencies regarding the manufacturing and sale of plasminogen

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]

Continue Reading

Global Market

Global Ornithine Transcarbamylase Deficiency Market is expected to grow at a CAGR of 12.4% from 2020 to 2027

Published

on

Press Release

Ornithine transcarbamylase is one of the six enzymes which is vital in the removal of excess nitrogen in the form of ammonia from the human blood. It is categorized as an inherited X- linked genetic disorder that occurs in more in the males as compared to the females. Lack of treatment will result in hyperammonemia which will cause coma, lethargy, loss of appetite and vomiting, etc.

Ammonia scavenging drugs are leading the treatment segment for the ornithine transcarbamylase (OTC) deficiency market. Prodrug such as glycerol phenylbutyrate and sodium phenylbutyrate forms an acetyl conjugate with the nitrogen present in the glutamine via the acetylation process in the detoxification organs such as liver and kidneys in order to facilitate the excretion of excess nitrogen via the urine. Gene therapy is going to register faster market growth in the near future owing to the strong product pipeline for the treatment of ornithine transcarbamylase (OTC) deficiency. Ultragenyx Pharmaceutical, Inc., has developed DTX-301 to deliver the OTC gene expression in a durable fashion to reduce its complications associated with clinical manifestation of this rare disease

Browse the full report Ornithine Trancarbamylase Deficiency Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027 at https://www.atlanticmarketresearch.com/ornithine-transcarbamylase-deficiency-market

Hospital pharmacy is currently leading the distribution channel segment for ornithine transcarbamylase (OTC) deficiency market. The vital factor which is related to its positive market growth is the presence of a hospital pharmacist for dispensing the medicines with precise posology prescribed by the physicians for the treatment of urea cycle disorder associated with ornithine transcarbamylase (OTC) deficiency. Retail pharmacy is going to embark on rampant market growth during the forecast period on account of the availability of ammonia scavenging drugs at a discounted price. Going forward the government healthcare agencies will be providing gene therapy drugs at a subsidized rate in the retail pharmacy to cater medical needs of low and middle-income groups households.

North America is dominating the geography segment for ornithine transcarbamylase (OTC) deficiency market. Significant increase in the number of newborn male babies suffering from ornithine transcarbamylase deficiency primarily drives its market growth in the region. Additionally domicile of major players such as Selecta Biosciences, Inc., Horizon Therapeutics, Plc., Phase Rx, Inc., etc. further propels the market growth in the region. Europe holds the second-largest market in the geography segment for ornithine transcarbamylase deficiency market. As per the European Commission report the prevalence rate of ornithine transcarbamylase deficiency in the neonates is 9 per 100,000 live births. The supportive regulatory environment provided by the European Medical Agency (EMA), by designating fast track status to the drug development for the treatment of ornithine transcarbamylase deficiency in the region. Asia Pacific is keen to register excellent market growth during the forecast period owing to the increasing trend of hospital pharmacy affiliated with corporate hospitals and increasing funds invested by government healthcare agencies for the drug development of rare diseases.

Biopharmaceutical companies actively engaged in providing medicines for the treatment of ornithine transcarbamylase deficiency are Merck KGaA., Phase Rx, Inc., Promethera Biosciences SA., Horizon Therapeutics, plc., Lucane Pharma SA., Swedish Orphan Biovitrum AB, Selecta Biosciences, Inc., Translate Bio, Inc., Ultragenyx Pharmaceutical, Inc., and Unicyte AG.

Market Key Takeaways:

  • Constant rise in the neonates worldwide suffering urea cycle disorder associated with ornithine transcarbamylase deficiency
  • Strong product pipeline comprising of gene therapy and stem cells transplantation to treat ornithine transcarbamylase (OTC) deficiency
  • Supportive regulatory environment provided by the healthcare agencies throughout the globe by awarding fast track designation for the drug development in treating OTC deficiency which is an orphan disease

About Atlantic Market Research

Atlantic Market Research is the largest provider of market research and consulting services.

Research and consulting services of Atlantic Market Research help businesses across the globe navigate the challenges in a rapidly growing marketplace with confidence. Our customized and syndicated market research reports deliver sufficient insights that drive sustainable growth.

Contact:
Mr. Trevor Wilson
Atlantic Market Research
911 Central Ave #268
Albany, NY 12206, USA

Website: https://www.atlanticmarketresearch.com
Email: [email protected]

Continue Reading

Trending

Copyright © 2019 Melanian News